{"nctId":"NCT00560950","briefTitle":"Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)","startDateStruct":{"date":"2007-07"},"conditions":["Pneumococcal Infection"],"count":143,"armGroups":[{"label":"1st Revaccination Group","type":"EXPERIMENTAL","interventionNames":["Biological: pneumococcal 23v polysaccharide vaccine"]},{"label":"2nd Revaccination Group","type":"EXPERIMENTAL","interventionNames":["Biological: pneumococcal 23v polysaccharide vaccine"]}],"interventions":[{"name":"pneumococcal 23v polysaccharide vaccine","otherNames":["V110","PNEUMOVAX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal or negative urine pregnancy test if female\n* No fever on the day of vaccination\n\nExclusion Criteria:\n\n* History of allergy to vaccine components\n* History of pneumococcal disease\n* Received any live virus vaccination within 4 weeks prior to study start\n* Received any inactivated vaccination within 7 days prior to study start\n* Received any blood products within 5 months prior to study start\n* Participated in an investigational drug or vaccine study in the past 30 days\n* Received immunosuppressive therapy\n* Patient has an immune deficiency","healthyVolunteers":true,"sex":"ALL","minimumAge":"59 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 3","description":"Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B,8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"0.7","spread":null},{"groupId":"OG003","value":"1.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 4","description":"Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"1.7","spread":null},{"groupId":"OG003","value":"3.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 6B","description":"Blood drawn at Day 1 and Day 30 of the\n\nextension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"3.0","spread":null},{"groupId":"OG003","value":"5.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 8","description":"Blood drawn at Day 1 and Day 30 of the\n\nextension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"9.3","spread":null},{"groupId":"OG002","value":"3.4","spread":null},{"groupId":"OG003","value":"7.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 9V","description":"Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"7.2","spread":null},{"groupId":"OG002","value":"4.1","spread":null},{"groupId":"OG003","value":"8.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 12F","description":"Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"0.8","spread":null},{"groupId":"OG003","value":"1.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 14","description":"Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"18.0","spread":null},{"groupId":"OG002","value":"10.3","spread":null},{"groupId":"OG003","value":"17.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 23F","description":"Blood drawn at Day 1 and Day 30 of the extension study were used to measure IgG antibody levels to 8 pneumococcal polysaccharide serotypes (3, 4, 6B, 8, 9V, 12F, 14, 23F) by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"4.7","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"5.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Pain (Injection site)","Fatigue","Pain","Swelling","Erythema"]}}}